Friday, May 6, 2022 2:00 PM – 4:00 PM ET Room B113–116
Immune-Based Therapeutics for Neurological Disease
- Giorgio Raimondi, Johns Hopkins Univ. Sch. of Med.
- Andrea Castillo, Eastern Washington Univ.
- Md Jahirul Islam, Seoul Natl. Univ. Col. of Med., Non-classical anti-inflammatory drugs (NCAIDs) ameliorates brain inflammation and improves memory in Alzheimer’s diseases mice model
- Jörg Wischhusen, Univ. Hosp. Wuerzburg, Alpha-synuclein peptides presented on chimeric MHC class Ib molecules prevent loss of substantia nigra neurons in an animal model for Parkinson’s disease
- Kevin G. Senior, Univ. of Florida Col. of Med., Novel gene immunotherapy prevents Aquaporin-4 (AQP4) mediated neuroinflammation and demyelination in a mouse model of multiple sclerosis
- Weikan Wang, Univ. of North Texas Hlth. Sci. Ctr., Aging impairs regulatory T cell (Treg) cells to affect late-onset (aged) multiple sclerosis (MS) – with the model of experimental autoimmune encephalomyelitis (EAE)
- Daniel Hwang, Thomas Jefferson Univ., CSF-1 maintains pathogenic but not homeostatic myeloid cells in the central nervous system during autoimmune neuroinflammation
- Javier Ochoa-Reparaz, Eastern Washington Univ., A GABA-producing probiotic for the protection of CNS demyelinating inflammation
- Gaurav Kumar, Oklahoma Med. Res. Fndn., Deficiency in B Cell Maturation Antigen reveals sex differences in Experimental Autoimmune Encephalomyelitis
- Giorgio Raimondi, Johns Hopkins Univ. Sch. of Med., Tolerogenic Artificial Antigen Presenting Cells for Selective Tolerance in Autoimmune Disease